Literature DB >> 14578918

Influence of losartan and atenolol on memory function in very elderly hypertensive patients.

R Fogari1, A Mugellini, A Zoppi, G Derosa, C Pasotti, E Fogari, P Preti.   

Abstract

The aim of this study was to compare the effect of the beta-adrenergic blocker atenolol and the Angiotensin II type 1 (AT1) receptor antagonist losartan on cognitive function in very elderly hypertensive patients. A total of 120 mild to moderate essential hypertensive (DBP >90 and <105 mmHg) patients, aged 75-89 years, were studied. After a 4-week wash-out period on placebo, they were randomized to receive atenolol 50 mg or losartan 50 mg for 24 weeks according to a parallel arm design. At the end of the placebo period and of each active treatment period, BP was measured (by mercury sphygmomanometer, Korotkoff I and V) and cognitive function was evaluated through three different tests (word list memory, word list recall and word list fluency). Both atenolol and losartan were equally effective in reducing SBP (-22.1 and -23.1 mmHg, respectively, P< 0.01 vs baseline) and DBP (-10.3 and -11.2 mmHg, respectively, P< 0.01 vs baseline). Atenolol treatment did not induce significant changes in any test score, whereas losartan significantly increased the score of both the word list memory (+2.2, P<0.05 vs baseline) and the word list recall test (+2.1, P<0.05 vs baseline). The comparison between losartan and atenolol was significant (P<0.05) for both memory tests. These data suggest that in very elderly hypertensive patients, chronic AT1 receptor blockade by losartan could improve cognitive function, in particular immediate and delayed memory.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578918     DOI: 10.1038/sj.jhh.1001613

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  35 in total

1.  Effects of treatment for hypertension on cognitive function in the elderly.

Authors:  Michael A Weber
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

Review 2.  The relationship between blood pressure and cognitive function.

Authors:  Vera Novak; Ihab Hajjar
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

3.  Role of central angiotensin receptors in scopolamine-induced impairment in memory, cerebral blood flow, and cholinergic function.

Authors:  Santoshkumar Tota; Kashif Hanif; Pradeep Kumar Kamat; Abul Kalam Najmi; Chandishwar Nath
Journal:  Psychopharmacology (Berl)       Date:  2012-02-24       Impact factor: 4.530

Review 4.  The vascular depression hypothesis: mechanisms linking vascular disease with depression.

Authors:  W D Taylor; H J Aizenstein; G S Alexopoulos
Journal:  Mol Psychiatry       Date:  2013-02-26       Impact factor: 15.992

Review 5.  Antihypertensive Therapies and Cognitive Function: a Review.

Authors:  Nisharahmed Kherada; Todd Heimowitz; Clive Rosendorff
Journal:  Curr Hypertens Rep       Date:  2015-10       Impact factor: 5.369

6.  Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.

Authors:  Thomas Simon O'Hagan; Whitney Wharton; Patrick Gavin Kehoe
Journal:  Am J Neurodegener Dis       Date:  2012-11-18

Review 7.  Effect of antihypertensive agents on quality of life in the elderly.

Authors:  Roberto Fogari; Annalisa Zoppi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 8.  Cognitive-enhancing effects of angiotensin IV.

Authors:  Paul R Gard
Journal:  BMC Neurosci       Date:  2008-12-03       Impact factor: 3.288

9.  Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis.

Authors:  Nien-Chen Li; Austin Lee; Rachel A Whitmer; Miia Kivipelto; Elizabeth Lawler; Lewis E Kazis; Benjamin Wolozin
Journal:  BMJ       Date:  2010-01-12

10.  Angiotensins and Alzheimer's disease: a bench to bedside overview.

Authors:  Patrick G Kehoe
Journal:  Alzheimers Res Ther       Date:  2009-07-09       Impact factor: 6.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.